{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T06:15:00Z","timestamp":1694672100416},"reference-count":47,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C Virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) Genotype 2 accounts for 10% of the patients with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> worldwide. The current standard of care (<jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>) in these patients is 24\u00a0weeks of Pegylated Interferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) plus Ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>), with sustained virological response rates (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) of 80\u201390%. However, there are subgroups of patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20102, such as those with advanced fibrosis\/cirrhosis, in whom <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates are still suboptimal, and highly responsive groups in whom <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates reach 95%. Treatment optimization is necessary to maximize efficacy in the former group and reduce treatment\u2010related side effects in the latter. Unfortunately, any attempt to modify the duration or dosing of the <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content> according to baseline factors has been disappointing and should not be continued at present. On the other hand on\u2010treatment <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> kinetics are fundamental for individualized treatment regimens because achieving negative <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> at week 4 (rapid virological response, <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content>) is the key factor when the duration of <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> is tailored in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20102 patients. Several studies have shown that treatment can be shortened to 16\u00a0weeks in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20102 patients with a <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content>, without increasing the risk of post\u2010treatment relapse, thus increasing tolerance to treatment while reducing healthcare costs. On the other hand, patients who do not achieve a <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content> correspond to a population of difficult\u2010to\u2010cure <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u20102 patients who need alternative treatment strategies which are not yet available.<\/jats:p>","DOI":"10.1111\/liv.12056","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T11:25:14Z","timestamp":1357212314000},"page":"35-40","source":"Crossref","is-referenced-by-count":12,"title":["How to optimize HCV therapy in genotype 2 patients"],"prefix":"10.1111","volume":"33","author":[{"given":"Eleonora","family":"Grassi","sequence":"first","affiliation":[{"name":"A.M. and A. Migliavacca Center for Liver Disease First Division of Gastroenterology Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"A.M. and A. Migliavacca Center for Liver Disease First Division of Gastroenterology Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02539.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2007.07.003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23252"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2012.32.3.210"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24503"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.08.001"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00328.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.048009"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25499"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.03.002"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.10.028"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1177\/135965350701200707","article-title":"Lack of rapid virological response predicts interferon\u2010alpha2b\/ribavirin therapy failure in HCV genotype 2 patients: a single\u2010centre study","volume":"12","author":"Rumi MG","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350901400415","article-title":"The pattern of pegylated interferon\u2010alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype","volume":"14","author":"Aghemo A","year":"2009","journal-title":"Antivir Ther"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.071"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25892"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00889.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.008"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24683"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2012.07.026"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.041"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.079"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.05.022"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23340"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042608"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102558"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20467"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.008"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24480"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22262"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21932"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02710.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.05.002"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_6_42_1","first-page":"259","article-title":"Antiviral activity of boceprevir monotherapy intreatment\u2010naive subjects with chronic hepatitis C genotype 2\/3","volume":"5","author":"Silva M","year":"2011","journal-title":"Hepatol Int"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.012"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.072"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.002"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.009"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.6135"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016464"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12056","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:17:00Z","timestamp":1694621820000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":47,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/liv.12056"],"URL":"https:\/\/doi.org\/10.1111\/liv.12056","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}